BLOG / 🇮🇳 India / sector intelligence · · daily

India Healthcare Pharma Policy Regulatory Filings — November 13, 2026

India Healthcare Policy

By Gunpowder Editorial ·

2 medium priority 2 total filings analysed

Executive Summary

Asarfi Hospital Limited delivered record Q2 FY27 results with revenue of ₹53.0 Cr (+18.1% YoY, +11.6% QoQ), EBITDA of ₹11.9 Cr (+34.0% YoY) and PAT of ₹6.1 Cr (+45.2% YoY), driving EBITDA margin to a record 22.4% (vs 19.9% YoY) and PAT margin to 11.6% (vs 9.6% YoY).

The growth was entirely driven by the Super-Specialty unit (revenue ₹41.3 Cr vs ₹32.2 Cr, +28% YoY) with strong contributions from Paediatrics & Neonatology (+78%), Neurosciences (+42%) and O&G (+41%), while the Cancer Hospital unit underperformed with revenue dipping to ₹11.6 Cr (from ₹11.9 Cr YoY), occupancy falling to 40% (vs 56% QoQ and 46% YoY) and Surgical Oncology revenue down 56%. Despite the mixed segment performance, the company maintained a healthy balance sheet with Debt-to-Equity at 0.52x and ROCE stable at 17% (TTM), though finance costs rose 19.3% YoY to ₹127 Lakhs. The filings highlight a clear portfolio shift towards high-margin super-specialty services, but the cancer unit's weakness warrants monitoring for a potential turnaround or strategic review. Overall, the results reflect strong operating leverage and margin expansion, but the divergence between segments creates a mixed investment case.

Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →

Tracking the trend? Catch up on the prior India Healthcare Pharma Policy Regulatory Filings digest from November 04, 2026.

Investment Signals (10)

  • ▲

    Revenue grew 18.1% YoY to ₹53.0 Cr, highest ever quarterly revenue, with EBITDA margin expanding 250 bps to 22.4% and PAT margin up 200 bps to 11.6%

  • ▲

    Super-Specialty unit revenue surged 28% YoY to ₹41.3 Cr, driven by Paediatrics & Neonatology (+78%), Neurosciences (+42%) and O&G (+41%), indicating strong demand for high-end services

  • ▲

    EBITDA grew 34% YoY to ₹11.9 Cr, outpacing revenue growth of 18%, demonstrating operating leverage and cost efficiency

  • ▲

    PAT increased 45.2% YoY to ₹6.1 Cr, with PAT margin improving to 11.6% from 9.6%

  • ▲

    Debt-to-Equity at 0.52x and ROCE at 17% (TTM) indicate a balanced capital structure and efficient capital utilization

  • ▲

    Finance costs rose 19.3% YoY to ₹127 Lakhs, slightly above revenue growth, but still manageable given the strong EBITDA growth

  • ▲

    Cancer Hospital unit revenue declined 2.5% YoY to ₹11.6 Cr, with occupancy dropping to 40% from 56% QoQ, signaling operational challenges

  • ▲

    Surgical Oncology revenue declined 56% YoY, a significant drag on overall growth and profitability

  • ▲

    Other income declined to ₹70.89 Lakhs from ₹79.75 Lakhs YoY, a minor negative but not material to overall performance

  • ▲

    General Surgery revenue declined 2% YoY, indicating weakness in conventional surgical services

Risk Flags (7)

Opportunities (6)

Sector Themes (5)

  • Healthcare Sector Growth (THEME)
    ◆

    Asarfi's strong revenue growth (+18% YoY) reflects robust demand for healthcare services in India, driven by increasing health awareness, insurance penetration, and government schemes like Ayushman Bharat

  • Margin Expansion in Healthcare (THEME)
    ◆

    Asarfi's EBITDA margin expansion to 22.4% (from 19.9%) indicates operating leverage and cost efficiencies, a trend likely seen across efficient hospital chains

  • Super-Specialty Focus (THEME)
    ◆

    The outperformance of super-specialty services (Paediatrics +78%, Neurosciences +42%) highlights a shift towards high-acuity, high-margin services in Indian private healthcare

  • Challenges in Oncology (THEME)
    ◆

    The decline in Asarfi's cancer unit (Surgical Oncology -56%) may reflect broader challenges in oncology care, such as competition from specialized cancer centers or reimbursement issues

  • Capital Structure Discipline (THEME)
    ◆

    Asarfi's Debt-to-Equity of 0.52x and ROCE of 17% suggest a focus on balanced growth and return on capital, a positive sign for the sector

Watch List (6)

Filing Analyses (2)
ASARFI HOSPITAL LIMITED Market Notice mixed materiality 7/10

13-11-2026

Asarfi Hospital Limited reported its highest-ever quarterly revenue of ₹53.0 Cr in Q2'FY27, up 18.1% YoY and 11.6% QoQ, with EBITDA rising 34.0% YoY to ₹11.9 Cr and PAT up 45.2% YoY to ₹6.1 Cr at a record 22.4% EBITDA margin. However, the Cancer Hospital unit showed weakness — revenue dipped to ₹11.6 Cr from ₹11.9 Cr YoY, occupancy fell to 40% (vs 56% in Q1'FY27 and 46% in Q2'FY26), and Surgical Oncology revenue declined 56% with Radiation Oncology down 18%. Super-Specialty unit drove growth with revenue up to ₹41.3 Cr from ₹32.2 Cr, led by Paediatrics & Neonatology (+78% YoY), Neurosciences (+42%) and O&G (+41%), while General Surgery declined 2%.

  • · Standalone revenue ₹5,287 Lakhs in Q2'FY27 vs ₹4,485 Lakhs in Q2'FY26 (+17.9% YoY)
  • · Standalone PAT ₹614 Lakhs vs ₹430 Lakhs (+42.7% YoY)
  • · Finance costs rose 19.3% YoY to ₹127 Lakhs
  • · Other expenses rose 16.3% YoY to ₹2,246 Lakhs (consolidated)
  • · Employee benefit expenses up 26.6% YoY to ₹775 Lakhs
  • · Cancer unit occupancy fell to 40% from 56% in Q1'FY27
  • · Super-Specialty occupancy recovered to 64% from 59% in Q1'FY27
  • · IPD patient volume 4,429 (+5% QoQ), OPD 41,285 (+13% YoY)
  • · Promotional coverage expanded from 7 to 10 districts
  • · Total effective beds 297 of 350 capacity
ASARFI HOSPITAL LIMITED Market Notice positive materiality 0/10

13-11-2026

Asarfi Hospital Limited reported record Q2 FY27 revenue of ₹5,287 Lakhs, up 18% YoY, with EBITDA rising 34% to ₹1,190 Lakhs and PAT increasing 43% to ₹614 Lakhs. EBITDA margin expanded to 22.5% from 19.9%, while PAT margin improved to 11.6% from 9.6%. However, other income declined to ₹70.89 Lakhs from ₹79.75 Lakhs, and ROCE remained flat at 17% (TTM) with Debt to Equity at 0.52x.

Get daily alerts with 10 investment signals, 7 risk alerts, 6 opportunities and full AI analysis of all 2 filings

₹500/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.

More from: India Healthcare Pharma Policy Regulatory Filings

🇮🇳 More from India

View all →